The product designated Xiexie Tuoke Cuchang Powder Veterinary Grade API is an unformulated, non-sterile active pharmaceutical ingredient in powder form intended for subsequent manufacture into tablets, injections, capsules, powders, granules, premixes, and solutions. The powder grade is supplied on a certificate of analysis and is not a finished veterinary medicinal product. Unless a specific batch is explicitly labelled sterile and depyrogenated, the material must be regarded as non-sterile and must be processed through the appropriate downstream microbial control steps. The grade identifier denotes the unprocessed powder presentation, as distinct from co-spray-dried, microencapsulated, granulated, or sterile lyophilized materials. Storage is controlled at 15–25 °C and relative humidity ≤60%; containers should be double polyethylene-lined fibre drums or equivalent moisture-barrier packaging, and each lot should be re-evaluated after opening. Quality systems for this material should align with ICH Q7 for active pharmaceutical ingredients and with the current good manufacturing practice requirements applicable to veterinary medicinal products in the intended market.

What release specification parameters govern powder acceptance for multi-dose veterinary formulations?

Release testing before use should include identity, assay, chromatographic purity, water, sulfated ash, residual solvents, elemental impurities, particle size, and microbial burden. The following acceptance ranges are typical for unformulated veterinary powder APIs of this class; the actual certificate of analysis for each lot must be the governing document because release criteria may differ by regulatory filing and manufacturing site. Identity is confirmed by infrared absorption or by comparison of HPLC retention time with a reference standard. Assay on the dried, solvent-free basis by HPLC or equivalent stability-indicating method is commonly specified as 98.0–102.0% w/w. Total related substances are typically controlled at ≤1.0% area, with individual unspecified impurities at ≤0.3% area unless a more stringent limit is justified by safety data. Water content is determined by Ph. Eur. 2.5.12 or USP <921> Method Ia; a limit of ≤2.0% w/w is common. Sulfated ash is determined by Ph. Eur. 2.4.14 or USP <281> with acceptance ≤0.1% w/w. Residual solvents are evaluated by Ph. Eur. 5.4 or USP <467> and should meet VICH GL18 or ICH Q3C limits; Class 1 solvents are prohibited, Class 2 solvents are limited by permitted daily exposure, and Class 3 solvents are limited to ≤5000 ppm or justified at higher levels. Elemental impurities are assessed under ICH Q3D and, where required for parenteral use, USP <232>/<233> or Ph. Eur. 5.20. Particle size is reported by laser diffraction according to Ph. Eur. 2.9.38 or USP <429>; the D90 should be controlled to the range agreed with the formulation site. Bulk density and tapped density are determined by Ph. Eur. 2.9.15 or USP <616>; a Hausner ratio ≤1.35 and Carr index ≤25% are preferred for direct compression. Microbial enumeration is conducted by Ph. Eur. 5.1.4 or USP <61>/<62>, with typical limits for oral solid APIs of total aerobic microbial count ≤10² CFU/g and total yeast and mould count ≤10² CFU/g, and absence of Escherichia coli.

For tablet and capsule manufacturing, the powder is blended with diluents, disintegrants, binders, and lubricants in equipment suited to the batch size. When direct compression is used, the unprocessed powder may require dry granulation if flow function coefficient is below 4 or if Hausner ratio exceeds 1.35. High-shear granulation for this class of veterinary APIs is often run in a 10 L or 25 L vertical granulator at impeller speed 300–500 min⁻¹ and chopper speed 1000–1500 min⁻¹, followed by fluid-bed drying at inlet temperature 50–60 °C to a final loss on drying of 1.0–2.0% w/w. Published data for this specific product configuration is limited; therefore these processing windows should be confirmed by design of experiments. A known production-scale failure mode is segregation after dilute-phase pneumatic conveying over distances greater than 10 m; blending after transfer reduces assay non-uniformity but does not replace acceptable particle-size overlap with excipients. Tablet sticking on rotary presses has been observed when residual moisture exceeded 2.5% w/w in formulations without adequate glidant; addition of 0.5–1.0% w/w colloidal silicon dioxide and 1.0–2.0% w/w lubricant is typical. For low-dose tablets below 25% w/w drug load, ordered mixing or geometric dilution is required, and content uniformity is tested according to Ph. Eur. 2.9.40 or USP <905>. Capsule filling on dosator machines may require tighter flow control than tamping-pin filling; batch-to-batch particle-size variance introduced by a milling screen change from 0.5 mm to 1.0 mm can alter bulk density by up to 15% and should trigger re-validation.

When the powder is intended for injectable or solution products, downstream aseptic processing becomes the controlling variable.

The API powder itself is not sterile; therefore injectable manufacturing requires dissolution, pH adjustment, bioburden reduction, and terminal sterilisation where thermostability allows, or aseptic filtration where it does not. The formulator must verify compatibility with water for injection, buffer species, tonicity agents, and preservatives. For a small-volume injectable, a typical target pH is 6.0–7.5; osmolality is adjusted with sodium chloride or dextrose, and the solution is passed through a 0.22 μm sterilising-grade filter in an EU GMP Annex 1 / FDA 21 CFR 210/211 classified area. The bacterial endotoxin limit for the finished parenteral veterinary product is usually 0.5 EU/mg or 0.5 EU/mL depending on dose; the powder lot should be tested by Ph. Eur. 2.6.14 or USP <85> unless a dedicated depyrogenation step is validated. If no endotoxin reduction claim is supplied for the powder, internal acceptance must be set by the formulator and the input material may require treatment by anion-exchange, ultrafiltration, or reverse osmosis after dissolution where compatible. Terminal sterilisation in an autoclave at 121 °C for 15 min or an equivalent F₀ ≥8 may be used for thermostable solutions; for heat-labile materials, aseptic filtration followed by fill-finish is necessary. Solutions produced from this powder must also be evaluated for particulate matter according to Ph. Eur. 2.9.19 or USP <788> and for sterility according to Ph. Eur. 2.6.1 or USP <71>. The powder is not supplied as a sterile lyophilized cake; a lyophilization cycle must be developed if a freeze-dried injectable is required.

Although premix and oral powder applications are often classified as low-risk, the undiluted nature of the powder introduces segregation and assay non-uniformity risks in low-dose feed manufacturing. For a target feed concentration of 50–200 g/tonne active ingredient, a sequential double dilution or ordered mixing step is required before addition to the final feed. Ribbon blenders with 20–40 rpm and 10–20 min mixing time may achieve coefficient of variation <5% when particle-size overlap is adequate; however, published data for this specific product configuration is limited and a mixing validation is required. Carryover in bucket elevators, drag conveyors, and hammermill systems should be evaluated by wash or flush trials; cross-contamination acceptance limits should follow the target animal species safety assessment and applicable toxicological thresholds. Residual solvent carryover, if any, is controlled by VICH GL18 or ICH Q3C. The powder should be protected from relative humidity above 60%; if moisture uptake is observed, pre-drying at 40–50 °C under vacuum or dry-air sweep is typical. Incompatibility with strong oxidizing agents, amine-based additives, or metal-ion-containing mineral premixes should be assessed; if chemical interaction is suspected, a design-of-experiment mixture study with assay and related-substance monitoring is required. The undiluted API contains no ground corn cob, lactose, or mineral oil carrier, so carryover risk is concentrated at the point of weighing and blending rather than distributed throughout a large-volume premix.

Sieve overlay limits and residual solvent selection in multi-source veterinary API procurement

The powder is characterized by particle-size distribution, often using Alpine air-jet sieving or laser diffraction. For dry blending, a D90 ≤300 μm is generally appropriate; wet granulation may tolerate larger primary particles because the granulation step controls final size. Multi-source procurement requires comparison of particle size, morphology, crystallinity, residual solvent profile, and impurity fingerprint; these attributes can alter dissolution, content uniformity, and processing behaviour. A supplier change without a bridging stability and dissolution study is not acceptable under ICH Q7 Section 12.5 and current veterinary GMP change-control provisions. Residual solvent limits follow ICH Q3C and VICH GL18; Class 1 solvents are unacceptable, Class 2 solvents are limited by permitted daily exposure, and Class 3 solvents are limited to ≤5000 ppm total. The powder differs from co-spray-dried dispersions in that it does not contain a polymer matrix and may require a separate solubilization or particle-size reduction step for poorly soluble actives. Differences from microencapsulated powders include the absence of a taste-masking or sustained-release coating; palatability for oral powders and feed premixes may therefore require flavour or encapsulation at the formulation stage. Differences from sterile lyophilized powders include the absence of a declared sterility assurance level and the absence of a ready-to-reconstitute matrix; injectable processes must add depyrogenation and sterile filtration as unit operations.

At a nominal concentration of 10 mg/mL, the powder is dissolved in purified water with pH adjustment; clarification through a 5 μm filter followed by a 0.45 μm prefilter is typical before terminal sterilisation for multi-dose oral solutions. For oral solution stability, microbial challenge testing according to Ph. Eur. 5.1.3 or USP <51> is required when the product is not a single-dose preserved solution. The powder’s residual water and hygroscopicity influence dissolution time; if water content is above 2.0% w/w, pre-drying may be required to avoid clumping during dispensing. Solutions should be monitored for pH drift, precipitation, and related substance increase at 25 °C/60% RH and 40 °C/75% RH according to the stability protocol. In high-shear mixing or homogenization steps for oral solutions, a rotor-stator mixer at 3000 rpm for 10 min may be used; however, excessive shear should be avoided if foaming or particle attrition is observed. Published data for this specific product configuration is limited; therefore the formulator must verify the dissolution endpoint by clarity, assay, and pH before scale-up.